

**To:** 5.1.2e [redacted] 5.1.2e [redacted] @wur.nl; 5.1.2e [redacted] @anses.fr; 5.1.2e [redacted] @anses.fr;  
 5.1.2e [redacted] @fli.de; 5.1.2e [redacted] @fli.de; 5.1.2e [redacted] @ucm.es; 5.1.2e [redacted] @ucm.es;  
 5.1.2e [redacted] @apha.gov.uk; 5.1.2e [redacted] @apha.gov.uk; 5.1.2e [redacted] @iss.it; 5.1.2e [redacted] @iss.it;  
 5.1.2e [redacted] @izs.it; 5.1.2e [redacted] @izs.it; 5.1.2e [redacted] @izsler.it; 5.1.2e [redacted] @izsler.it;  
 5.1.2e [redacted] @rivm.nl; 5.1.2e [redacted] @rivm.nl;  
 5.1.2e [redacted] @piwet.pulawy.pl; 5.1.2e [redacted] @piwet.pulawy.pl;  
 5.1.2e [redacted] @iniav.pt; 5.1.2e [redacted] @iniav.pt; 5.1.2e [redacted] @sva.se; 5.1.2e [redacted] @sva.se;  
 5.1.2e [redacted] @ages.at; 5.1.2e [redacted] @ages.at; 5.1.2e [redacted] @fli.de; 5.1.2e [redacted] @fli.de;  
 5.1.2e [redacted] @pasteur.fr; 5.1.2e [redacted] @pasteur.fr; 5.1.2e [redacted] @vri.cz; 5.1.2e [redacted] @vri.cz;  
 5.1.2e [redacted] @sciensano.be; 5.1.2e [redacted] @sciensano.be; 5.1.2e [redacted] @inia.es; 5.1.2e [redacted] @inia.es

**Cc:** 5.1.2e [redacted] @vetinst.no

**From:** 5.1.2e [redacted]

**Sent:** Thur 4/23/2020 1:06:08 PM

**Subject:** SV: COVID19 proposal EJP One Health\_partner description

**Received:** Thur 4/23/2020 1:07:27 PM

[NVI partner description.docx](#)

Hi 5.1.2e [redacted] et al.,

Thanks for your email.

I have asked one of our most senior virologists to lead NVIs participation in this call from now on. As 5.1.2e [redacted] for the entire Institute, I confess that it is difficult for me to follow this in detail 5.1.2e [redacted] Besides in the hands of my colleague 5.1.2e [redacted] ... this endeavour is in much better hands ☺

So here follows NVIs summary in 10 lines and I would appreciate if you edit your records and also copy 5.1.2e [redacted] 5.1.2e [redacted] @vetinst.no from now on (I will follow this up nonetheless until we land a final draft for approval to SSB) ☺

Good and amazing work so far so thanks for your and 5.1.2e [redacted] coordination!

Best regards from Norway

5.1.2e [redacted]

5.1.2e [redacted]

NORWEGIAN VETERINARY INSTITUTE

5.1.2e [redacted]

M +47

5.1.2e [redacted]

5.1.2e [redacted] @vetinst.no | <http://www.vetinst.no/ansatte/carlos-goncalo-das-neves>

 **Cristin**

**Fra:** 5.1.2e [redacted] <5.1.2e [redacted]@wur.nl>

**Sendt:** mandag 20. april 2020 16:35

**Til:** 5.1.2e [redacted] @anses.fr <5.1.2e [redacted]@anses.fr>; 5.1.2e [redacted] @fli.de  
 <5.1.2e [redacted]@fli.de>; 5.1.2e [redacted] @ucm.es <5.1.2e [redacted]@ucm.es>; 5.1.2e [redacted] @apha.gov.uk  
 <5.1.2e [redacted]@apha.gov.uk>; 5.1.2e [redacted] @iss.it <5.1.2e [redacted]@iss.it>; 5.1.2e [redacted] @izs.it <5.1.2e [redacted]@izs.it>;  
 5.1.2e [redacted] @izsler.it <5.1.2e [redacted]@izsler.it>; 5.1.2e [redacted] @rivm.nl  
 <5.1.2e [redacted]@rivm.nl>; 5.1.2e [redacted] @rivm.nl <5.1.2e [redacted]@rivm.nl>; 5.1.2e [redacted]  
 <5.1.2e [redacted]@vetinst.no>; 5.1.2e [redacted] @piwet.pulawy.pl <5.1.2e [redacted]@piwet.pulawy.pl>;  
 5.1.2e [redacted] @iniav.pt <5.1.2e [redacted]@iniav.pt>; 5.1.2e [redacted] @sva.se <5.1.2e [redacted]@sva.se>;  
 5.1.2e [redacted] @ages.at <5.1.2e [redacted]@ages.at>; 5.1.2e [redacted] @fli.de <5.1.2e [redacted]@fli.de>; 5.1.2e [redacted] @pasteur.fr  
 <5.1.2e [redacted]@pasteur.fr>; 5.1.2e [redacted] <5.1.2e [redacted]@vri.cz>; 5.1.2e [redacted] @sciensano.be <5.1.2e [redacted]@sciensano.be>;  
 5.1.2e [redacted] @inia.es <5.1.2e [redacted]@inia.es>

Emne: RE: COVID19 proposal EJP One Health\_partner description

Dear all,

As contact person for your institutes in the Covid19 internal proposal of the EJP One Health, I would like to ask you to forward a partner description of **Max 10 lines**

- Name of organisation, scientific contact person for the organisation
- Summary of major activities and competencies of this person over the last 5 years.
- Spread over the EU regions (N, E, S, W)
- Expertise: animal or public health, feed, food and environment
- Information that indicates skills to manage international projects.

Example attached

Thank you

Regards

5.1.2e

5.1.2e

Global One Health

Wageningen BioVeterinary Research,  
Department of Virology,  
Houtribweg 39, 8221 RA, Lelystad,  
The Netherlands,  
T +31 320 5.1.2e  
M +31 6 5.1.2e  
E 5.1.2e @wur.nl

(more information about 5.1.2e on [Twitter](#), [LinkedIn](#), [ResearchGate](#) )

[www.wageningenur.nl/en/](http://www.wageningenur.nl/en/)

(follow us on: [Twitter](#), [Linkedin](#))

Disclaimer:

This e-mails and any attachments may contain confidential information. If you are not the intended recipient, please notify the sender and 5.1.2e @wur.nl immediately, permanently delete the message and remove it from your server. Any use, dissemination or publication of the information (in whole or in part) is prohibited.

Wageningen University & Research is the name of the collaboration between Wageningen University (Dutch Chamber of Commerce Number 09215846) and Wageningen Research Foundation (Dutch Chamber of Commerce Number 09098104).

From: 5.1.2e

Sent: 14 April 2020 21:05

To: 5.1.2e <5.1.2e@surrey.ac.uk>; 5.1.2e @iss.it' <5.1.2e @iss.it>; 5.1.2e @iss.it'  
<5.1.2e @iss.it>; 5.1.2e @ages.at' <5.1.2e @ages.at>; 5.1.2e @izs.it' <5.1.2e @izs.it>;  
5.1.2e @izsler.it' <5.1.2e @izsler.it>; 5.1.2e <5.1.2e @pasteur.fr>; 5.1.2e  
5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @sva.se>; 5.1.2e <5.1.2e  
5.1.2e @sva.se>; 5.1.2e <5.1.2e @fli.de>; 5.1.2e <5.1.2e @fli.de>; 5.1.2e  
<5.1.2e @apha.gov.uk>; 5.1.2e <5.1.2e @vri.cz>; 5.1.2e <5.1.2e @vetinst.no>;  
5.1.2e <5.1.2e @anses.fr>; 5.1.2e @rivm.nl'  
<5.1.2e @rivm.nl>  
Cc: 5.1.2e <5.1.2e @sva.se>; 5.1.2e <5.1.2e @sciensano.be>; 5.1.2e  
<5.1.2e @anses.fr>; 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e  
<5.1.2e @wur.nl>

Subject: RE: COVID19 proposal EJP One Health

Dear all,

Some more info about the drafting of the Covid19 JIP proposal:

Attached please find an overview of inputs for the Covid19 JIP proposal, we have received from partners (excel-file).

Also attached a table with names and email addresses of the appointed WP-leaders.

Additional suggestions (or modifications of such) can be included in the excel-file (and returned to me).

Feel free to forward these files to other interested OHEJP partner institutes as well.

The WP leaders will be asked to start working on WP descriptions, using this excel-file.

Cheers

5.1.2e

5.1.2e

Global One Health

Wageningen BioVeterinary Research,  
Department of Virology,  
Houtribweg 39, 8221 RA, Lelystad,  
The Netherlands,  
T +31 320 5.1.2e  
M +31 6 5.1.2e  
E 5.1.2e @wur.nl

(more information about 5.1.2e on [Twitter](#), [LinkedIn](#), [ResearchGate](#) )

[www.wageningenur.nl/en/](http://www.wageningenur.nl/en/)

(follow us on: [Twitter](#), [LinkedIn](#))

Disclaimer:

This e-mails and any attachments may contain confidential information. If you are not the intended recipient, please notify the sender and 5.1.2e @wur.nl immediately, permanently delete the message and remove it from your server. Any use, dissemination or publication of the information (in whole or in part) is prohibited.

Wageningen University & Research is the name of the collaboration between Wageningen University (Dutch Chamber of Commerce Number 09215846) and Wageningen Research Foundation (Dutch Chamber of Commerce Number 09098104).

From: 5.1.2e

Sent: 03 April 2020 15:34

To: 5.1.2e <5.1.2e@surrey.ac.uk>; 5.1.2e @iss.it' <5.1.2e@iss.it>; 5.1.2e @iss.it'  
<5.1.2e@iss.it>; 5.1.2e @ages.at' <5.1.2e@ages.at>; 5.1.2e @izs.it' <5.1.2e@izs.it>;  
<5.1.2e@izsler.it>; 5.1.2e @izsler.it>; 5.1.2e @pasteur.fr>; 5.1.2e  
5.1.2e @rivm.nl>; 5.1.2e @sva.se>; 5.1.2e @sva.se>;  
5.1.2e @fli.de>; 5.1.2e @fli.de>; 5.1.2e @vetinst.no>;  
<5.1.2e@apha.gov.uk>; 5.1.2e @vri.cz>; 5.1.2e @vetinst.no>;  
5.1.2e @anses.fr>; 5.1.2e @rivm.nl'  
<5.1.2e@rivm.nl>  
Cc: 5.1.2e <5.1.2e@sva.se>; 5.1.2e @sciensano.be>; 5.1.2e  
<5.1.2e@anses.fr>; 5.1.2e @rivm.nl>

Subject: COVID19 proposal EJP One Health

Dear all,

This email is to follow up on our Letter of Intent for a COVID19 Joint Integrative Project within the EJP One Health. It is send to all contacts of partners that have shown an interest in participating in this JIP. (additional partners to be included).

Last Wednesday the LoI (and additional inputs) has been discussed by the OHEJP PMT:



It was agreed that we proceed drafting a full JIP proposal. Estimated available budget 2-3Meuro (full budget, 44% EU contribution). Deadline full draft proposal 31 May. Reviewing by SSB and PMT. Final proposal by 30 June 2020. I will try to pull this together with [redacted] (UoS)

In line with the LoI, we propose to aim for 7 Work Packages:

- WP0: Coordination and communication
- WP1: Development and harmonization of SARS-CoV2 detection methods
- WP2: SARS-CoV2 detection in clinical samples
- WP3: SARS-CoV2 detection in food and feed specimens
- WP4: SARS-CoV2 characterization
- WP5: Alignment with SARS-CoV2 surveillance
- WP6: Novel Coronavirus preparedness

Next step will be to identify WP leaders, so please let me know if you have an interest in leading one of the above WPs.

If you hear of another partner who is interested in participating in the JIP proposal, please advise to send me an email.

Looking forward to hear from you,  
More information to follow soon.

Cheers

[redacted]

[redacted]

Global One Health

Wageningen BioVeterinary Research,  
Department of Virology,  
Houtribweg 39, 8221 RA, Lelystad,  
The Netherlands,  
T +31 320 [redacted]  
M +31 6 [redacted]  
E [redacted]@wur.nl

(more information about [redacted] on [Twitter](#), [LinkedIn](#), [ResearchGate](#) )  
[www.wageningenur.nl/en/](http://www.wageningenur.nl/en/)  
(follow us on: [Twitter](#), [Linkedin](#))

Disclaimer:

This e-mails and any attachments may contain confidential information. If you are not the intended recipient, please notify the sender and [redacted]@wur.nl immediately, permanently delete the message and remove it from your server. Any use, dissemination or publication of the information (in whole or in part) is prohibited.

Wageningen University & Research is the name of the collaboration between Wageningen University (Dutch Chamber of Commerce Number 09215846) and Wageningen Research Foundation (Dutch Chamber of Commerce Number 09098104).